Top

Inflammation Research

Published in:

01-01-2014 | Review

Role of Angptl4 in vascular permeability and inflammation

Authors: Liang Guo, Shao-Ying Li, Fu-Yun Ji, Yun-Feng Zhao, Yu Zhong, Xue-Jun Lv, Xue-Ling Wu, Gui-Sheng Qian

Published in: Inflammation Research | Issue 1/2014

Abstract

Background

Angptl4 is a secreted protein involved in the regulation of vascular permeability, angiogenesis, and inflammatory responses in different kinds of tissues. Increases of vascular permeability and abnormality changes in angiogenesis contribute to the pathogenesis of tumor metastasis, ischemic-reperfusion injury. Inflammatory response associated with Angptl4 also leads to minimal change glomerulonephritis, wound healing. However, the role of Angptl4 in vascular permeability, angiogenesis, and inflammation is controversy. Hence, an underlying mechanism of Angptl4 in different kind of tissues needs to be further clarified.

Methods

Keywords such as angptl4, vascular permeability, angiogenesis, inflammation, and endothelial cells were used in search tool of PUBMED, and then the literatures associated with Angptl4 were founded and read.

Results

Data have established Angptl4 as the key modulator of both vascular permeability and angiogenesis; furthermore, it may also be related to the progression of metastatic tumors, cardiovascular events, and inflammatory diseases. This view focuses on the recent advances in our understanding of the role of Angptl4 in vascular permeability, angiogenesis, inflammatory signaling and the link between Angptl4 and multiple diseases such as cancer, cardiovascular diseases, diabetic retinopathy, and kidney diseases.

Conclusions

Taken together, Angptl4 modulates vascular permeability, angiogenesis, inflammatory signaling, and associated diseases. The use of Angptl4-modulating agents such as certain drugs, food constituents (such as fatty acids), nuclear factor (such as PPARα), and bacteria may treat associated diseases such as tumor metastasis, ischemic-reperfusion injury, inflammation, and chronic low-grade inflammation. However, the diverse physiological functions of Angptl4 in different tissues can lead to potentially deleterious side effects when used as a therapeutic target. In this regard, a better understanding of the underlying mechanisms for Angptl4 in different tissues is necessary.

Goddard LM, Iruela-Arispe ML. Cellular and molecular regulation of vascular permeability. Thromb Haemost. 2013;109:407–15.PubMedCrossRef

Armulik A, Genové G, Mäe M, Nisancioglu MH, Wallgard E, Niaudet C, et al. Pericytes regulate the blood-brain barrier. Nature. 2010;468:557–61.PubMedCrossRef

Daneman R, Zhou L, Kebede AA, Barres BA. Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature. 2010;468:562–6.PubMedCentralPubMedCrossRef

Mehta D. Signalling mechanisms regulating endothelial permeability. Physiol Rev. 2006;86:279–367.PubMedCrossRef

Dvorak AM, Feng D. The vesiculo-vacuolar organelle (VVO). A new endothelial cell permeability organelle. J Histochem Cytochem. 2001;49:419–32.PubMedCrossRef

Miyawaki-Shimizu K, Predescu D, Shimizu J, Broman M, Predescu S, Malik AB. siRNA-induced caveolin-1 knockdown in mice increases lung vascular permeability via the junctional pathway. Am J Physiol Lung Cell Mol Physiol. 2006;290:L405–13.PubMedCrossRef

Thennes T, Mehta D. Heterotrimeric G proteins, focal adhesion kinase, and endothelial barrier function. Microvasc Res. 2012;83:31–44.PubMedCentralPubMedCrossRef

Sun Z, Li X, Massena S, Kutschera S, Padhan N, Gualandi L, et al. VEGFR2 induces c-Src signalling and vascular permeability in vivo via the adaptor protein TSAd. J Exp Med. 2012;209:1363–77.PubMedCentralPubMedCrossRef

Thibeault S, Rautureau Y, Oubaha M, Faubert D, Wilkes BC, Delisle C, et al. S-nitrosylation of beta-catenin by eNOS-derived NO promotes VEGF-induced endothelial cell permeability. Mol Cell. 2010;39:468–76.PubMedCrossRef

10.

Mammoto T, Parikh SM, Mammoto A, Gallagher D, Chan B, Mostoslavsky G, et al. Angiopoietin-1 requires p190 RhoGAP to protect against vascular leakage in vivo. J Biol Chem. 2007;282:23910–8.PubMedCrossRef

11.

Yao Q, Shin MK, Jun JC, Hernandez KL, Aggarwal NR, Mock FR, et al. Effect of chronic intermittment hypoxia on triglyceride uptake in different tissues. J Lipid Res. 2013;54:1058–65.PubMedCrossRef

12.

Zhu PC, GOH YY, Alison HF. Angiopoietin-like 4: a decade of research. Biosci Rep. 2011;32:211–9.CrossRef

13.

Valenzuela DM, Griffiths JA, Rojas J, Aldrich TH, Jones PF, Zhou H, et al. Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. Proc Natl Acad Sci USA. 1996;96:1904–9.CrossRef

14.

Wiesner G, Morash BA, Ur E, Wilkinson M. Food restriction regulates adipose-specific cytokines in pituitary gland but not in hypothalamus. J Endocrinol. 2004;180:R1–6.PubMedCrossRef

15.

Koliwad SK, Kuo T, Shipp LE, Gray NE, Backhed F, Wang JC, et al. Angiopoietin-like 4(ANGPTL4, fasting-induced adipose factor) is a direct glucocorticoid receptor target and participates in glucocorticoid-regulated triglyceride metabolism. J. BiolChem. 2009;284:25593–601.

16.

Kersten S, Mandard S, Tan NS, Escher P, Metzger D, Chambon P, et al. Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferators-activated receptor target gene. J Biol Chem. 2000;275:28488–93.PubMedCrossRef

17.

Kersten S, Lichtenstein L, Steenbergen E, Mudde K, Hendriks HJ, Hesselink MK, et al. Caloric restriction and exercises increase plasma ANGPTL4 levels in humans via elevated free fatty acids. Arterioscler Thromb Vasc Biol. 2009;29:969–74.PubMedCrossRef

18.

Padua D, Zhang XHF, Wang Q, Nadal C, Gerald WL, Gomis RR, et al. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell. 2008;133:66–77.PubMedCentralPubMedCrossRef

19.

Clement LC, Avila-Casado C, Mace C, Soria E, Bakker WW, Kersten S, et al. Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome. Nat Med. 2011;17:117–22.PubMedCentralPubMedCrossRef

20.

Galaup A, Cazes A, Le Jan S, Phlippe J, Connault E, CozE Le, et al. Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness. Proc Natl Acad Sci USA. 2006;103:18721–6.PubMedCrossRef

21.

Huang RL, Teo Z, Chong HC, Zhu P, Tan MJ, Tan CK, et al. ANGPTL4 modulates vascular junction integrity by integrin signaling and disruption of intercellular VE-cadherin and claudin-5 clusters. Blood. 2011;118:3990–4002.PubMedCrossRef

22.

Katanasaka Y, Kodera Y, Kitamura Y, Morimoto T, Tamura T, Koizumi F. Epidermal growth factor receptor variant type III markedly accelerates angiogenesis and tumor growth via inducing c-myc mediated angiopoietin-like 4 expression in malignant glioma. Mol Cancer. 2013;25:12–31.

23.

Perdiguero EG, Galaup A, Durand M, Teillon J, Phillippe J, Valenzuela DM, et al. Alteration of developmental and pathological retinal angiogenesis in angptl4-deficient mice. J Biol Chem. 2011;286:36841–51.PubMedCrossRef

24.

Mandard S, Zandbergen F, Tan NS, Escher P, Patsouris D, Koenig W, et al. The direct peroxisome proliferator-activated receptor target fasting-induced adipose factor (FIAF/PGAR/ANGPTL4) is present in blood plasma as a truncated protein that is increased by fenofibrate treatment. J Biol Chem. 2004;279:34411–20.PubMedCrossRef

25.

Ge H, Yang G, Huang L, Motola DL, Pourbahrami T, Li C. Oligomerization and regulated proteolytic processing of angiopoietin-like protein 4. J Biol Chem. 2004;279:2038–45.PubMedCrossRef

26.

Lei X, Shi F, Basu D, Huq A, Routhier S, Day R, et al. Proteolytic processing of angiopoietin-like protein 4 by proprotein convertases modulates its inhibitory effects on lipoprotein lipase activity. J Biol Chem. 2011;286:15747–56.PubMedCrossRef

27.

28.

Stapleton CM, Joo JH, Kim Y-S, Liao G, Panettieri RA Jr, Jetten AM. Induction of ANGPTL4 expression in human airway smooth muscle cells by PMA through activation of PKC and MAPK pathways. Exp Cell Res. 2010;316:507–16.PubMedCentralPubMedCrossRef

29.

Yang YH, Wang Y, Lam KS, Yau MH, Cheng KK, Zhang J, et al. Supression of the Raf/MEK/ERK signaling cascade and inhibition of angiogenesis by the carboxyl terminus of angiopoietin-like protein 4. Arterioscler Thromb Vasc Biol. 2008;28:835–40.PubMedCrossRef

30.

Ito Y, Olike Y, Yasunaga K, Hamada K, Miyata K, Matsumoto SI, et al. Inhibition of angiogenesis and vascular leakiness by angiopoietin-related protein 4. Cancer Res. 2003;63:6651–7.PubMed

31.

Hutchings H, Ortega N, Plouet J. Extracellular matrix-bound vascular endothelial growth factor promotes endothelial cell adhesion, migration, and survival through integrin ligation. FASEB J. 2003;17:1520–2.PubMed

32.

Okochi-Takada E, Hattori N, Tsukamoto T, Miyamoto K, Ando T, Ito S, et al. ANGPTL4 is a secreted tumor suppressor that inhibits angiogenesis. Oncogene. 2013; 174 [Epub ahead of print].

33.

Le Jan S, Amy C, Cazes A, Monnot C, Lamande N, Favier J, et al. Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma. Am J Pathol. 2003;162:1521–8.PubMedCrossRef

34.

Goh YY, Pal M, Chong HC, Zhu P, Tan MJ, Punugu L, et al. Angiopoietin-like 4 interacts with matrix proteins to modulate wound healing. J Biol Chem. 2010;285:32999–3009.PubMedCrossRef

35.

Galaup A, Gomez E, Souktani R, Durand M, Cazes A, Monnot C, et al. Protection aganist myocardial infarction and no-reflow through preservation of vascular integrity by angptl4. Circulation. 2012;125:140–9.PubMedCrossRef

36.

Quintero P, Gonzalez-Muniesa P, Martinez JA. Influence of different oxygen supply on metabolic markers and gene response in murine adipocytes. J Biol Requl Homeost Agents. 2012;26:379–88.

37.

Lichtenstein L, Mattijssen F, de Wi NJ, Georgiadi A, Hooiveld GJ, van der Meer R, et al. ANGPTL4 protects against severe proinflammatory effects of saturated fat by inhibiting fatty acid uptake into mesenteric lymph node macrophages. Cell Metab. 2010;12:580–92.PubMedCentralPubMedCrossRef

38.

Brown R, Imran SA, Wilkinson M. Lipopolysaccharide (LPS) stimulates adipokine and socs3 gene expression in mouse brain and pituitary gland in vivo, and in N-1 hypothalamic neurons in vitro. J Neuroimmunol. 2009;209:96–103.PubMedCrossRef

39.

Lu B, Moser A, Shigenaga JK, Grunfeld C, Feingold KR. The acute phase response stimulates the expression of angiopoietin like protein 4. Biochem Biophys Res Commun. 2010;391:1737–41.PubMedCrossRef

40.

Rummel C, Inoue W, Sachot C, Poole S, Hubschle T, Luheshi GN. Selective contribution of interleukin-6 and leptin to brain inflammatory signals induced by systemic LPS injection in mice. J Comp Neurol. 2008;511:373–95.PubMedCrossRef

41.

Zhu P, Tan MJ, Huang RL, Tan CK, Chong HC, Pal M, et al. Angiopoietin-like 4 protein elevates the prosurvival intracellular O₂ ⁻:H₂O₂ ratio and confers anoikis resistance to tumors. Cancer Cell. 2011;19:401–15.PubMedCrossRef

42.

Nakayama T, Hirakawa H, Shibata K, Nazneen A, Abe K, Naqayasu T, et al. Expression of angiopoietin-like 4(ANGPTL4) in human colorectal cancer: ANGPTL4 promotes venous invasion and distant metastasis. Oncol Rep. 2011;25:929–35.PubMedCrossRef

43.

Shibata K, Nakayama T, Hirakama H, Hidaka S, Naqayasu T. Clinicopathological significance of angiopoietin-like protein 4 expression in oesophageal squamous cell carcinoma. J Clin Pathol. 2010;63:1054–8.PubMedCrossRef

44.

Ma T, Jham BC, Hu J, Friedman ER, Basile JR, Molinolo A, et al. Viral G protein-coupled receptor up-regulates angiopoietin-like 4 promoting angiogenesis and vascular permeability in Kaposi’s sarcoma. PNAS. 2010;107:14363–8.PubMedCrossRef

45.

Reiser J. Filtering new facts about kidney disease. Nat Med. 2011;17:44–5.PubMedCrossRef

46.

Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev. 2003;83:835–70.PubMed

47.

Goh YY, Pal M, Chong HC, Zhu P, Tan MJ, Punugu L, et al. Angiopoietin-like 4 interacts with integrins beta1 and beta5 to modulate keratinocyte migration. Am J Pathol. 2010;177:2791–803.PubMedCrossRef

48.

Musso G, Gambino R, Cassader M. Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes. Annu Rev Med. 2011;62:361–80.PubMedCrossRef

49.

Lichtenstein L, Berbée JF, van Dijk SJ, van Dijk KW, Bensadoun A, Kema IP, et al. Angptl4 upregulates cholesterol synthesis in liver via inhibition of LPL- and HL-dependent hepatic cholesterol uptake. Arterioscler Thromb Vasc Biol. 2007;27:2420–7.PubMedCrossRef

50.

Adachi H, Fujiwara Y, Kondo T, Nishikawa T, Ogawa R. Angptl 4 deficiency improves lipid metabolism, suppresses foam cell formation and protects against atherosclerosis. Biochem Biophys Res Commun. 2009;379:806–11.PubMedCrossRef

51.

Romeo S, Pennacchio LA, Fu Y, Boerwinkle E, Tybjaerg-Hansen A, Hobbs HH, et al. Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nat Genet. 2007;39:513–6.PubMedCentralPubMedCrossRef

52.

Folsom AR, Peacock JM, Demerath E, Boerwinkle E. Variation in ANGPTL4 and risk of coronary heart disease: the atherosclerosis risk in communities study. Metabolism. 2008;57:1591–6.PubMedCentralPubMedCrossRef

53.

Jonker JT, Smit JW, Hammer S, Snel M, van der Meer RW, Lamb HJ, et al. Dietary modulation of plasma angiopoietin-like protein 4 concentrations in healthy volunteers and in patients with type 2 diabetes. Am J Clin Nutr. 2013;97:255–60.PubMedCrossRef

54.

Xu A, Lam MC, Chan KW, Wang Y, Zhang J. Angiopoietin-like protein 4 decreases blood glucose and improves glucose tolerance but induces hyperlipidemia and hepatic steatosis in mice. Proc Natl Acad Sci USA. 2005;102:6086–91.PubMedCrossRef

55.

Yokouchi H, Eto K, Nishimura W, Takeda N, Kaburagi Y, Yamamoto S, et al. Angiopoietin-like protein 4 (ANGPTL4) is induced by high glucose in retinal pigment epithelial cells and exhibits potent angiogenic activity on retinal endothelial cells. Acta Ophthalmol. 2013;91:e289–97.PubMedCrossRef

56.

Bouleti C, Mathivet T, Coqueran B, Serfaty JM, Lesaqe M, Berland E, et al. Protective effects of angiopoietin-like 4 on cerebrovascular and functional damages in ischaemic stroke. Eur Heart J. 2013; [Epub ahead of print].

Title: Role of Angptl4 in vascular permeability and inflammation
Authors: Liang Guo
Shao-Ying Li
Fu-Yun Ji
Yun-Feng Zhao
Yu Zhong
Xue-Jun Lv
Xue-Ling Wu
Gui-Sheng Qian
Publication date: 01-01-2014
Publisher: Springer Basel
Published in: Inflammation Research / Issue 1/2014
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI: https://doi.org/10.1007/s00011-013-0678-0

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Role of Angptl4 in vascular permeability and inflammation

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2014

Associations between PTPN2 polymorphisms and susceptibility to ulcerative colitis and Crohn’s disease: a meta-analysis

Microgravity inhibition of lipopolysaccharide-induced tumor necrosis factor-α expression in macrophage cells

Inflammatory factor-specific sumoylation regulates NF-κB signalling in glomerular cells from diabetic rats

OxLDL-induced IL-1beta secretion promoting foam cells formation was mainly via CD36 mediated ROS production leading to NLRP3 inflammasome activation

Flavones derived from nature attenuate the immediate and late-phase asthmatic responses to aerosolized-ovalbumin exposure in conscious guinea pigs

The role of the immune system in idiopathic nephrotic syndrome: a review of clinical and experimental studies

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page